Pelage is developing a topical hair follicle stem celltherapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
User discusses 4.5 months of using 0.5 DUT & 5 mg Oral Min for hair loss. They share progress pictures and discuss styling options and shedding experiences.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
HairClone is developing cell replacementtreatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism aboutthe need for crowdfunding.